Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

Condition:   Renal Cell Carcinoma Interventions:   Drug: Nivolumab;   Drug: Ipilimumab Sponsor:   Kidney Cancer Research Bureau Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials